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Background: Serum free light chain difference (FLC-diff) and cardiac specific factors are validated diagnostic and prognostic tools in 
evaluating prognosis in patients with amyloidosis. However, their utility in those newly diagnosed with cardiac light chain (AL) amyloidosis 
has not yet been tested.
methods: We performed a retrospective analysis of patients with newly diagnosed cardiac AL amyloidosis at our institution. A Cox 
Proportional Hazards Model was used to assess the association of serum FLC-diff and traditional markers of heart failure (HF) severity at 
the time of diagnosis with a composite endpoint of one year mortality, LVAD implantation or heart transplantation after controlling for age, 
hypertension, diabetes, smoking and renal function.
results: In 178 subjects (29% kappa, 71% lambda, age 65.2 +/- 10.9 y, 60% male, 40% female), the median baseline serum FLC-diff was 
250 mg/L, Troponin T 0.09 ng/mL, NT-proBNP 5986 pg/mL, BNP 1018 pg/mL and ejection fraction (EF) 50%. Mortality was 65% at one 
year. A baseline FLC-diff > 250mg/L, positive troponin, EF under 50%, NYHA Class 3 or 4 HF and elevated BNP or NT-proBNP above the 
median were predictive of the composite endpoint.
conclusion:  Serum assessment of FLC-diff as well as traditional markers of HF severity were significantly correlated with one year 
mortality, LVAD implantation or need for heart transplantation in patients with newly diagnosed cardiac AL amyloidosis after controlling for 
age, hypertension, diabetes, smoking and renal function.
 
